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OBJECTIVES: To assess the cost-effectiveness of paricalcitrol IV
in the management of eligible hemodialysis (HD) patients with
secondary hyperparathyroidism (SHPT), in comparison with
standard oral vitamin D treatment. METHODS: A decision tree
model was used to estimate the cost-effectiveness of paricalcitrol
IV for HD patients with increased serum PTH levels despite stan-
dard treatment (K/DOQI guidelines). The primary perspective of
the study was that of the Dutch society in 2005. Costs and clin-
ical outcomes were discounted at 4%. The data sources included
published literature, paricalcitrol IV clinical trials, ofﬁcial
price/tariff lists and national population statistics. RESULTS:
The base case analysis from the society perspective shows that
paricalcitrol IV generates cost savings of €1714 per patient over
three years compared to standard oral vitamin D treatment
(€27,817 vs. €29,531). Paricalcitrol IV also saves 0.10 Life Years
(2.37 vs. 2.27) and leads to a gain in 0.08 QALYs (1.07 vs. 0.99).
When the analysis is performed from the health insurance per-
spective, the total cost savings reduce from €1,714 to €983, but
paricalcitrol IV remains dominant over standard oral vitamin D
treatment. Potential savings in the paricalcitrol IV treatment arm
are to be contributed to a reduction of hospitalization. Gain in
utilities is to be contributed to a decreased hospitalization rate
and increased survival of the paricalcitrol IV treated population
Sensitivity analysis showed that the outcomes were only moder-
ately sensitive to the changes in input variables for the model,
but paricalcitrol IV remained dominant in all analyses. CON-
CLUSION: This study showed that paricalcitrol IV is a cost-
saving option in the treatment of HD patients presenting SHPT
in comparison to standard oral vitamin D treatment in The
Netherlands. Introduction of paricalcitrol IV to the Dutch reim-
bursement system would propagate costs savings and a gain in
life years as well as QALYs.
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Intracerebral hemorrhage (ICH) is a devastating form of stroke,
resulting in mortality and disability. A recent Phase IIb clinical
trial has shown that recombinant factor VIIa (rFVIIa, Novo-
Seven) signiﬁcantly reduces mortality in ICH patients and
improves functional outcome. OBJECTIVES: To estimate short-
term cost-effectiveness of rFVIIa compared to standard care 
in treating ICH from a US hospital (inpatient) perspective.
METHODS: A decision-analytic model was developed to esti-
mate the cost-effectiveness of rFVIIa 40mcg/kg, 80mcg/kg, and
160mcg/kg compared to standard care in treating ICH from a
hospital perspective. Costs and outcomes were estimated for a
patient’s initial hospitalization. Mortality, disability, and initial
hospital length of stay (LOS) was obtained from the Phase IIb
clinical trial. Direct medical costs for initial hospitalization fol-
lowing ICH were assumed to include all costs associated with
inpatient care estimated from an analysis of Medicare claims
data. rFVIIa costs were based on average sales price. Costs were
in 2005 US dollars. Sensitivity analyses were conducted to assess
robustness. RESULTS: Treatment with rFVIIa 40mcg/kg and
160mcg/kg resulted in additional costs of $2283 and $6700
respectively compared to standard care, which includes the cost
of rFVIIa, after factoring in relevant inpatient costs. Treatment
with rFVIIa 80mcg/kg was associated with a reduction in
expected medical costs (-$333). Given the clinical trial results,
the incremental cost-effectiveness ratio (ICER) per survivor for
rFVIIa 40mcg/kg, 80mcg/kg, and 160mcg/kg were $19,726, 
-$3178 (cost-savings), and $68,723 respectively. In addition,
average costs per survivor for rFVIIa 40mcg/kg, 80mcg/kg, 
160mcg/kg, and standard care groups were $44,102, $41,475,
$50,582 and $48,085, respectively. Results were robust to
changes in model parameters. CONCLUSIONS: Treating ICH
with rFVIIa 80mcg/kg is not only cost-effective but also cost-
saving to the hospital in the short-term compared to standard
care. Cost-effectiveness results were driven by treatment efﬁcacy
(mortality), LOS (and corresponding inpatient costs), and rFVIIa
costs.
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OBJECTIVE: To evaluate the cost-effectiveness of DES com-
pared to BMS using outcome data derived from a cardiac patient
registry in Ontario. METHODS: A decision analytic model with
a 1 year time frame was used to estimate costs and effects
(QALYS, revascularizations) for patients receiving DES and
BMS. Prospectively collected data from the Cardiac Care
Network of Ontario patient registry was used to estimate revas-
cularization rates along with other key clinical variables to pop-
ulate the model. Stent costs were obtained from manufacturers,
while revascularizations costs (PCI, CABG) were obtained from
a hospital in southern Ontario. Utility values applied to time
with angina, post revascularization, and otherwise healthy
patients were estimated using results from the ARTS trial. Para-
meter uncertainty was assessed by means of probabilistic sensi-
tivity analysis. Cost-effectiveness was assessed on 22 unique
patient subgroups based on diabetes status, lesion characteristics
(length and diameter) and AMI within 7 days. RESULTS: Using
clinical outcome data from 7953 PCI cases, the cost-effectiveness
of DES was most favorable in non-post MI diabetes patients with
long and narrow lesions $223,000/QALY ($9869/revaculariza-
tion). This subgroup had the greatest difference in estimated 
1 year revascularization rates between BMS and DES (20.6% 
vs. 6.0%). Cost effectiveness was found to be greater than
$500,000/QALY ($20,788/revascularization) in 17 of the 22
patient cohorts (85% of patients). CONCLUSIONS: The current
analysis found that the cost-effectiveness of DES to be high in
all patient subgroups. The primary strength of the analysis is that
revascularization rates and other key model input variables were
based upon a large sample of “real world” patient data. Other
published economic analyses of drug eluting and bare metal
stents are at least partially based upon clinical trial data in which
clinical beneﬁts of DES are exaggerated compared to “real
world” practice, thus providing more favorable, but misleading,
cost-effectiveness results.
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